Derms on Drugs

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.We cover:Can moisturizing infants prevent atopic dermatitis?New sunscreen ingredients headed for the US marketInsights from lichenoid eruptions linked to immune checkpoint inhibitorsWhat to do if oral JAKs fail in alopecia areataDoes CeraVe outperform other moisturizers?The real risk of cardiovascular and thromboembolic events with JAK inhibitorsWhy IL-13 inhibitors differ in likelihood of causing arthralgiasAdvances in autologous skin cell transplantation for vitiligoThe safety of patients self-injecting triamcinolone for acneNew findings on hypersensitivity reactions after sentinel lymph node biopsyCan patch testing help with burning mouth syndrome?A drug that reduces cardiovascular mortality in hidradenitis suppurativaNovel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosisJoin us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.Listen now and stay ahead in dermatology!

The Derms on Drugs are back at it, answering the burning derm questions you didn't even know you had.  Join us this week as we dive into more "outside the box" therapies that you can use next week in the office.-Is low dose naltrexone a lifeline in difficult dermatoses or a false hope?-There's been some chatter around metformin for hidradenitis suppurativa.  Is it hype or hope?-Diet and chronic spontaneous urticaria - Patients always ask and while we know it isn't food allergy, new data says that diet does play a role and gives us a simple intervention that's worth trying.-Everybody hates warts and we're always looking for pain free treatment options - could a heating pad and hydrogen peroxide be the answer?-Can we knock out psoriasis long term with a few months of high dose IL-23 inhibition?-We love tranexamic acid for melasma, but does oral or topical work better?-Once a vitiligo patient gets better, can you stop the Opzelura?-Fact or Fiction:  Compared to PLEVA, PLC lasts longer and happens in adults more than kids?

The Derms on Drugs are joined by Dr. Peter Lio to take a dive into the "root causes" of atopic dermatitis and what we can do to address them.  Maybe you've heard about the "NICE" Axis - the Neuro-Immuno-Cutaneo-Endocrine Axis and thought you were on the cutting edge.  Well, you're not.  The new and updated model is the "SINGE" Network - the Skin-Immuno-Neuro-Gastro-Endocrine Network.  Join us this week to get the answers to more of the questions you didn't know you should have!New data confirms again that elimination diets don't help with atopic dermatitis and data shows that avoiding foods makes you more likely so how do you talk to patients who are convinced food allergy is driving their atopic dermatitis?Should you be recommending probiotics to you atopic dermatitis patients (and which one)?How (and why) do probiotics work for atopic dermatitis?What does a lion in your basement have to do with atopic dermatitis?How do you handle patients who say that all moisturizers sting when you put them on?How do you deal with people in whom Staph aureus is playing a major role in their atopic dermatitis?What's coming for atopic dermatitis in 2026?

This week's episode will help you not get sued, talk to psoriasis patients about diet, manage transplant patients with skin cancer and more.  Join us again this week to get the answers to burning dermatology questions you didn't know you had.   Can the Mediterranean diet help with psoriasis?  And why do people get 'gluten sensitivity' from US wheat but not Mediterranean wheat?When do you recommend changing immunosuppression in transplant patients with skin cancer?Are people with atopic dermatitis more or less likely to have contact derm than other people?Hailey Hailey is an awful disease that's hard to treat - can dupilumab help?  What other 'off the beaten path' therapies are there?Cosibelimab is the new kid on the block for bad squamous cell carcinoma - is it any better than existing treatments?When do you need to be worried about underlying malignancy in dermatomyositis patients?Oral minoxidil causes hairy arms in men.  But do they care?You know Bactrim can cause SJS and TEN, but do you know about the other life threatening side effect that specifically affects young healthy people with acne?

The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology.  Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists!  As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):Is AI going to make our lives easier or is it going to replace us?How good is AI at answering patient questions?Will patients accept "AI Providers"?How can you start levering AI now to make your life better?What AI tools are out there to start using right now?Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question:  What came first, the chicken or the egg?  You'll have to listen to find out.  What's a Mazotti Reaction and why do you care?How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?Can a steroid nasal spray help for Chronic Spontaneous Urticaria?Do biologics reduce infection risk in AD more than JAK Inhibitors and why?How does superficial radiation therapy compare to Mohs for skin cancer?Dermal hyperpigmentation is impossible to treat - can isotretinoin help?Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why). In this episode:·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?·       HS & spondyloarthritis: are you screening… should you be?·       JAKs and the heart: are all cardiovascular risks created equal?·       “2/3 HS remission” headlines: why this data shouldn’t change your practice·       Tirbanibulin + cryo for AKs: combo win or marketing math?·       Hydrochlorothiazide & skin cancer: do you really need that conversation?·       Oral minoxidil + Olumiant: synergy or wishful thinking in AA?·       OX40/OX40L blockers: exciting pathway—new hope or new hype? Fast. Practical. Slightly skeptical (for good reason).If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:-Is isotretinoin making kids short?  -Is Dupixent making them tall?  -What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  -What OTC supplement makes NBUVB work better for vitiligo?  -What oral drug can you add to isotretinoin to make it work even better?  -Does oral tranexamic acid increase the risk of blood clots when used in dermatology?-How well does Opzelura work for hidradenitis suppurativa?-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?-What common statistical technique used by pharma is total BS?-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones? 

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.Here’s what we’re tackling:What hits harder on anxiety and depression—scarring or non-scarring alopecia?How tightly does AA severity track with psychological burden?How should you approach the mental health effects of AA?(Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).Here’s what we’re tackling:Do herbal supplements turn up dermatomyositis?Can biologics cut down on blood clots in HS?Wait… does Claritin supercharge isotretinoin?Is Sotyktu stirring up rosacea?How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?Any fresh weapons against demodex?Anything new for those stubborn pemphigus oral lesions?What to do when your patient is resistant to multiple botulinum toxins?And—holy grail alert—can we actually prevent chemo-induced alopecia in breast cancer?

The Derms on Drugs are joined by Dr. Crystal Aguh from Johns Hopkins for an AMAZING discussion on central centrifugal scarring alopecia.  From uber practical, cheap, safe, effective treatment approaches to deep science on what is happening in this disease, listen this week and you'll be an expert - how to talk to these patients, the baseline treatments everybody should be on, when to get more aggressive, when to step therapy back - the whole enchilada.  We even throw in a little frontal fibrosing alopecia.  Quite honestly one of the best episodes we've ever done.  The Derms on Drugs learned new approaches to this disease and we promise, you will too!

Join us this week as the Derms on Drugs crew discusses the latest in the Dermatology literature.  Topics for this episode include: - Cutaneous vasculitis of the skin (it’s a Chapel Hill thing)- Ozempic face, butt, and body- TAC injections for AA – what concentration do you use?- Does the MERLIN study deserve its magical name?- Are systemic JAK inhibitors the answer for vitiligo?- And everyone’s favorite – Demodex mites!

You don't see a lot of kids with psoriasis, but when you do it can be a big challenge, especially if it's bad and they need a systemic.  The Derms on Drugs are coming to the rescue!  We'll have a special guest - Dr. Doug Kress (who was heavily involved in training all three of the Derms on Drugs) who has enormous experience treating pediatric psoriasis.  We'll get into all the stuff you really need to know:-What systemic drugs are approved for psoriasis under the age of 18?-What does the data say about which ones work the best?-How good is Tremfya, the first IL-23 inhibitor approved in kids, and where will it fit?-How is psoriasis in kids different from psoriasis in adults?-What are the roles of the different topicals approved for psoriasis in kids?-How do we think about therapy selection differently in kids vs adults?-Do kids get psoriatic arthritis?-What about shots vs pills in kids?-How do you talk to parents about the different biologics for kids?-How do you handle vaccines in kids who are psoriasis biologics?-Do you ever use methotrexate in kids?

Brought to you by Scholars In Medicine  The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like:  -Do tattoos protect people against melanoma? -What cheap, easy topical works great for fissures in hand eczema? -Is Dupixent safe in pregnancy? -Are tinted sunscreens actually better than regular mineral sunscreens for melasma? -If an alopecia areata patient has failed two or three JAKs, is it worth trying another one? -What does the early data show for systemic JAK efficacy in vitiligo? -Is there anything better than triamcinolone to inject keloids with? -Does some crazy drug Patton found an article about work for hemodialysis associated itch?  So, join us for another episode that'll make you better at what you do while you're having fun listening! 

Join the Derms on Drugs and Dr. Shanthi Narla as we dive into the world of obesity, GLP-1s and dermatology.  Whatever you think about all of these topics, we promise that your patients are hearing about them, reading about them and will be asking about them.  Specifically, we'll get into the latest data about how GLP-1s affect diseases like psoriasis, hidradenitis suppurativa and atopic dermatitis and we'll even touch on if dermatologists should be prescribing GLP-1s.  So, while there aren't any definite answers out there yet, tune in this week and you'll be ready when these hot topics come up!

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.In this episode, we tackle:-What network meta-analyses actually measure and how they're conducted-Why two NMAs can reach opposite conclusions about drug effectiveness-Red flags to watch for when evaluating NMA quality and reliability-Practical guidance for incorporating NMA findings into clinical practicePerfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.Listen now to become a smarter consumer of dermatology research! And be sure to discover more at Scholars In Medicine!

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers. We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above.  Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!So join us for a deep dive into CSU, and yes, there will be trivia at the end!Visit the ⁠Scholars In Medicine⁠ website for more.